Related Experiment Videos
The use of azlocillin to treat serious infections
Abstract:
Azlocillin, a semisynthetic ureidopenicillin that inhibits many Gram-negative and Gram-positive bacteria and many Pseudomonas aeruginosa resistant to carbenicillin, was used to treat 23 episodes of infection in 20 patients. The majority of the patients had severe underlying diseases, including marked reduction in renal function in a number of the patients. Infection sites were lung, urinary tract, skin and primary bacteraemia. Seven patients had bacteraemia. Clinical cure or improvement was achieved in 87% of infections, all patients with bacteraemia due to Pseudomonas spp., Escherichia coli, Listeria spp. and Streptococcus faecalis were cured. Cure was achieved with azlocillin against carbenicillin-resistant Ps. aeruginosa infections. Serum and urine levels were easily maintained in excess of the accepted minimal inhibitory concentrations of the susceptible organism (less than or equal to 64 mg/l). Adverse effects were minor. Azlocillin was a safe, well-tolerated and effective agent to treat suspected or proven infections due to Ps. aeruginosa and other susceptible bacteria.
Insights
Azlocillin effectively treated severe bacterial infections, including those resistant to carbenicillin. This ureidopenicillin demonstrated high cure rates, even in patients with compromised renal function, showing it is a safe and well-tolerated treatment option.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Microbiology
Background:
- Severe bacterial infections pose significant challenges, particularly in immunocompromised patients.
- Antibiotic resistance, especially to carbenicillin in Pseudomonas aeruginosa, necessitates novel therapeutic agents.
- Ureidopenicillins offer a promising class of antibiotics for multidrug-resistant Gram-negative pathogens.
Purpose of the Study:
- To evaluate the efficacy and safety of azlocillin in treating severe bacterial infections.
- To assess azlocillin's effectiveness against carbenicillin-resistant Pseudomonas aeruginosa.
- To determine azlocillin's pharmacokinetic profile in patients with underlying diseases and renal impairment.
Main Methods:
- A prospective study involving 20 patients with 23 episodes of severe bacterial infections.
- Azlocillin administration and monitoring of serum and urine drug concentrations.
- Clinical and microbiological assessment of treatment outcomes, including cure rates and adverse effects.
Main Results:
- Azlocillin achieved an 87% clinical cure or improvement rate across various infection sites.
- Complete cure was observed in all patients with bacteremia caused by Pseudomonas spp., Escherichia coli, Listeria spp., and Streptococcus faecalis.
- Effective treatment of carbenicillin-resistant Pseudomonas aeruginosa infections was achieved with azlocillin.
- Therapeutic serum and urine azlocillin levels were maintained above minimal inhibitory concentrations (≤64 mg/l).
- Adverse effects associated with azlocillin were minor and well-tolerated.
Conclusions:
- Azlocillin is a safe, well-tolerated, and effective antibiotic for treating severe infections caused by susceptible bacteria, including Pseudomonas aeruginosa.
- Azlocillin provides a valuable therapeutic option for infections resistant to other antibiotics like carbenicillin.
- The drug's favorable pharmacokinetic profile supports its use in patients with severe underlying conditions and renal dysfunction.